Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | CA7 | P43166 | 2/20 | 0.66 |
| ▸ | CA9 | Q16790 | 2/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.60 |
| ▸ | FASN | P49327 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CCR1 | P32246 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8154103 | 0.90 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8154098 | 0.87 | CA12 (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8155110 | 0.87 | SLC6A7 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3641801 | 0.86 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8161638 | 0.84 | USP2 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1581499 | 0.83 | MEN1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8155716 | 0.79 | CYP3A4 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2229509 | 0.78 | MEN1 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8150776 | 0.78 | FASN (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL97240 | 0.78 | CA12 (0.67) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | CA12 4508/4885CA1 3512/4885CA2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.